AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
Intellia Therapeutics Soars 11.05% on Gene Therapy Success
Generated by AI AgentAinvest Pre-Market Radar
Tuesday, Jun 17, 2025 6:16 am ET1min read
Intellia Therapeutics (NASDAQ:NTLA) surged 11.05% in pre-market trading on June 17, 2025, driven by positive developments in its gene therapy programs.
Intellia's gene therapy for hereditary angioedema (HAE) has shown a 98% reduction in attacks, reinforcing the company's leadership in the field. This significant efficacy data has bolstered investor confidence in the company's pipeline.
Analysts from H.C. Wainwright have reiterated their Buy rating and $30.00 price target for
Therapeutics, citing the promising results from the company's clinical trials. This positive outlook has contributed to the stock's recent gains.Wolfe Research has also upgraded Intellia Therapeutics from a "peer perform" rating to an "outperform" rating, setting a $21.00 price target. This upgrade reflects the growing optimism surrounding the company's therapeutic advancements.
Intellia's three-year data on Lonvo-z, a gene-editing therapy for HAE, has shown a 98% reduction in attacks after a single dose. This long-term efficacy data further validates the potential of Intellia's gene-editing technologies.
Ainvest Pre-Market Radar
Get the scoop on pre-market movers and shakers in the US stock market.
Latest Articles
Regenxbio shares surge 7.99% on renewed investor confidence in strategic direction and clinical progress.
Dec.22 2025
Metallus Inc. (MTUS) plunges 6.73% as divergent analyst ratings and earnings scrutiny drive pre-market selloff.
Dec.22 2025
Oracle shares jumped 6.63% on Dec. 22 2025 on AI cloud growth forecast and strategic alliances.
Dec.22 2025
Nvidia shares surged 3.93% in pre-market Dec. 22 trading on renewed confidence in AI and data center demand.
Dec.22 2025
Personalis (NASDAQ:PSNL) surges 7.89% on renewed investor confidence driven by strategic direction and collaborations
Dec.22 2025
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments

No comments yet